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Abstract 
Obesity and excessive lipolysis are implicated in preeclampsia. Intrauterine growth restriction is 
associated with low maternal body mass index and decreased lipolysis. Our aim was to assess 
how maternal and offspring fatty acid metabolism is altered in mothers in the third trimester of 
pregnancy with preeclampsia (n=62) or intrauterine growth restriction (n=23) compared to 
healthy pregnancies (n=164). Markers of lipid metabolism and erythrocyte fatty acid 
concentrations were measured. Maternal adipose tissue fatty acid composition and mRNA 
expression of adipose tissue fatty acid metabolizing enzymes and placental fatty acid transporters 
were compared. Mothers with preeclampsia had higher plasma triglyceride (21%, p<0.001) and 
non-esterified fatty acid (50%, p<0.001) concentrations than Controls. Concentrations of major 
n-6 and n-3 long chain polyunsaturated fatty acids in erythrocytes were 23-60% lower (all 
p<0.005) in preeclampsia and intrauterine growth restriction mothers and offspring compared to 
Controls. Subcutaneous adipose tissue ∆-5 and ∆-6 desaturase and very long chain fatty acid 
elongase mRNA expression was lower in preeclampsia than Controls [Control 3.38(2.96) vs 
preeclampsia 1.83(1.91), p=0.030; 3.33(2.25) vs 1.03(0.96), p<0.001; 0.40 (0.81) vs 0.00 (0.00), 
p=0.038 (square root) expression relative to control gene respectively]. Low maternal and fetal 
long chain polyunsaturated fatty acid concentrations in preeclampsia may be the result of 
decreased maternal synthesis.  
 
Key words: fatty acid, pregnancy, pre-eclampsia, intrauterine growth restriction 
 3 
Introduction 
Pre-eclampsia (PE), a multi-system disorder particular to pregnancy, is a leading cause of 
maternal and neonatal morbidity and mortality.  Preeclampsia is characterized by widespread 
endothelial dysfunction, resulting in hypertension due to vasoconstriction, proteinuria 
attributable to glomerular damage and oedema secondary to increased vascular permeability. 
Maternal obesity, increased insulin resistance and aberrant fatty acid metabolism are involved in 
its pathogenesis1. Excessive non-esterified fatty acid (NEFA) flux in PE, similar to that seen in 
non-alcoholic fatty liver disease, may instigate ectopic lipid accumulation in the liver and other 
tissues2 and interfere with long chain polyunsaturated fatty acid (LC PUFA) synthesis3. 
Intrauterine growth restriction (IUGR) can occur independently or simultaneously with PE. 
Isolated IUGR pregnancies are characterized by low maternal BMI, low plasma lipid levels and 
reduced lipolysis4, 5. Few data exist on the impact of PE or IUGR on maternal fatty acid 
mobilisation during pregnancy and that available has focussed on percentage of total fatty acids 
in plasma6-9 rather than absolute amounts or erythrocyte composition. These latter measures 
allow primary independent effects on individual fatty acids to be determined and better reflect 
tissue fatty acid composition and long term nutritional status rather than recent dietary intake10. 
Long chain polyunsaturated fatty acids of the n-3 and n-6 series such as docosahexaenoic acid 
(22:6n-3, DHA) and arachidonic acid (20:4n-6) are required for fetal growth11 and brain 
development12. Thus a potential long term consequence of disturbed LC PUFA synthesis in PE is 
sub-optimal neurodevelopment of the infants13. Maternal LC PUFA are mobilized by week 13 of 
gestation14 but their source(s) are not established. The n-6 and n-3 LC PUFA are synthesized 
from essential shorter chain precursors (18:2n-6 and 18:3n-3 respectively) via ∆5-desaturase, ∆6-
desaturase and elongase enzymes (Figure S1). Pregnant women accumulate adipose tissue in the 
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early anabolic stage of pregnancy but in later gestations, due to insulin resistance, adipose tissue 
fatty acid mobilization increases15. Placental transfer of LC PUFA to the fetus is obligatory12 and 
both circulating NEFA and fatty acids released from lipolysis of lipoprotein triglycerides are 
transported across the placenta by a series of fatty acid binding and transfer proteins16. Amongst 
these, pFABPpm a membrane transporter, and FABP7, an intracellular transporter, have high 
affinities for 22:6n-3 and are expressed by trophoblasts17-19. 
We hypothesized that, in an analogous way to non-alcoholic fatty liver disease, excessive NEFA 
flux in PE provokes ectopic lipid accumulation in the liver and inhibits LC PUFA synthesis. Our 
aim was to assess whether maternal fatty acid metabolism is altered in mothers with PE or IUGR 
compared to healthy pregnancy and impacts on offspring LC PUFA status. We carried out 
erythrocyte fatty acid compositional analysis of paired maternal and fetal samples from healthy 
and complicated pregnancies. Markers of lipid metabolism were also assessed to describe the 
gross differences in fuel metabolism. To assess whether LC PUFA status was related to the 
composition of stored fatty acids we analysed both visceral and upper body subcutaneous 
adipose tissue fatty acid composition in a subset of the pregnancies. The mRNA expression of 
desaturase and elongase enzymes was quantitated in adipose tissue as a marker of LC PUFA 
synthesis in this and other tissues. To test whether offspring LC PUFA status was related to 
placental transfer of fatty acids, mRNA expression of key enzymes and transporters in LC PUFA 
metabolism was quantitated in placental biopsies.  
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Methods 
Subjects 
Subjects with PE (n=62), with IUGR (n=23) and Controls with uncomplicated pregnancies 
(n=164) in the third trimester of a singleton pregnancy were recruited. The study was approved 
by the Glasgow Royal Infirmary Local Research Ethics Committee and women gave written 
informed consent. For further details on recruitment and biopsy sampling see the Online 
Supplement.  
 
Biochemical analyses 
Total cholesterol, triglyceride and HDL cholesterol20, glucose and high sensitivity CRP assays21 
were performed by Clinical Biochemistry, Glasgow Royal Infirmary. Other analytes were 
assayed using commercially available kits (Online Supplement). Fatty acids were extracted from 
erythrocyte membranes14 and adipose tissue and identified by gas chromatography14, 22 (details in 
Online Supplement).  
Messenger RNA expression 
Total RNA was isolated from placenta (Control n=57, PE n=17 and IUGR n=11), subcutaneous 
adipose tissue (Control n=50, PE n=12 and IUGR n=13) and visceral adipose tissue (Control 
n=25, PE n=12 and IUGR n=5) and cDNA synthesized. Target gene expression was quantitated 
relative to a control gene by Taqman real time PCR using commercial primer probe sets 
(Applied Biosystems) (details in Online Supplement).  
 
Statistical analysis 
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Details of statistical analysis are provided in the Online Supplement. Unsaturation index (UI) is 
the average number of double bonds per fatty acid residue multiplied by 100; average chain 
length (CL) is the sum of mol% times chain length for each reported fatty acid divided by 100; 
C20-22 is the total percentage of LC PUFA with ≥20 carbon units; DHA deficiency index is 
22:5n-6/22:4n-6 and EFA deficiency index is (n-3+n-6)/(n-7+n-9). Due to multiple testing 
significance levels were set at P<0.005 for plasma metabolic markers and fatty acid analysis. 
 7 
Results 
Maternal metabolic and inflammatory profile  
Maternal antenatal booking characteristics (Table S1) and third trimester plasma profiles (Table 
S2) are shown. Mothers with PE had higher triglyceride, NEFA, leptin, adiponectin and IL-6 
than Controls, and these differences were maintained after adjustment for maternal BMI, parity, 
smoking status and gestational age at sampling.  
 
The impact of PE and IUGR on maternal LC PUFA status 
Maternal third trimester erythrocyte fatty acid concentrations are shown in Table 1. There were 
no differences in concentrations of saturated fatty acids (SAFA) between groups apart from a 
lower concentration of the minor fatty acid 22:0 in IUGR. For the monounsaturated fatty acids 
(MUFA) there was a 19% lower concentration of 24:1n-9 in IUGR. Concentrations of all n-6 
PUFA, apart from the minor fatty acids 18:3n-6 and 22:2n-6, were 23% to 60% lower in both PE 
and IUGR mothers. Of the n-3 PUFA, 22:5n-3 and 22:6n-3 were lower in PE and IUGR mothers 
to a similar extent as for the n-6 PUFA. Interestingly, 20:5n-3 was not different between groups. 
 
Summary indices of maternal fatty acid status are shown in Table 1. The percentage SAFA is 
higher and the percentage unsaturated fatty acids and PUFA significantly lower in PE and IUGR. 
The main driver for the change in proportions is the lower PUFA as concentrations of SAFA are 
similar between groups. The lower PUFA concentrations account for the lower unsaturation 
index and average chain length observed in PE and IUGR. Since concentrations of both n-6 and 
n-3 PUFA are lower, the n-6/n-3 ratio is similar across groups. PE and IUGR mothers are 
deficient in EFA and 22:6n-3. All observed differences were maintained after adjustment for 
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potential confounders. Women with severe PE had significantly lower concentrations than those 
with mild PE for the majority of fatty acid parameters measured (Table S3). There was no 
relationship with gestational age at PE onset (data not shown). 
 
Offspring metabolic and inflammatory profile 
Cord blood total cholesterol, but not HDL, concentration was significantly higher in PE offspring 
(Table S2). Conversely both total and HDL cholesterol concentrations were lower in IUGR 
compared to Control offspring. Cord blood triglyceride concentrations were higher in PE and 
IUGR offspring compared to Controls. There were no differences in cord blood NEFA, glucose, 
insulin, HOMA or inflammatory marker levels between groups. Cord blood leptin (46-68%) and 
adiponectin (38-60%) levels were significantly lower in PE and IUGR offspring, associations 
which were lost after adjusting for maternal BMI and gestation at delivery for leptin and 
maternal smoking for adiponectin as described by others23-25. 
 
The impact of PE and IUGR on offspring LC-PUFA status 
Cord blood erythrocyte SAFA concentrations were similar between groups apart from higher 
levels of the minor fatty acids 14:0 and 17:0 in PE and IUGR (Table 2).  There were no 
differences in MUFA concentrations between groups. There were significantly lower 20:3n-6, 
22:4n-6 and 22:5n-6 concentrations in PE and IUGR and a trend towards reduced 20:4n-6. 
Similar to their mothers, there were significantly lower concentrations of 22:5n-3 and 22:6n-3 in 
PE and IUGR offspring. The lower 22:5n-3 concentration was lost on adjustment for 
confounders, particularly parity. Interestingly, there was a trend towards higher 18:3n-3 
concentration in PE and IUGR.  
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Summary measures for cord blood erythrocytes are shown in Table 2. The pattern in cord blood 
is the same as that observed in their mothers i.e. a higher proportion of SAFA and a reduced 
proportion of unsaturated fatty acids and PUFA, driven by the lower levels of PUFA. PE 
offspring had lower 22:6n-3 and were classed as being EFA deficient, whereas in IUGR 
offspring there was only a trend towards a deficiency in 22:6n-3 and EFA. The study was 
underpowered to examine the impact of severity of preeclampsia on offspring fatty acid 
composition. 
 
Figure 1 shows percent maternal and cord blood PUFA concentrations relative to the Control 
concentration for PE (Fig 1A) and IUGR (Fig 1B). Values below 100% indicate a relative fatty 
acid deficiency compared to Controls. IUGR and PE maternal fatty acids levels are all deficient 
apart from 20:5n-3. Cord blood levels of PUFA were deficient to a lesser degree than mothers. 
For the majority of PUFA the relative deficiency in the IUGR offspring is less than that in PE but 
this did not reach statistical significance due to high inter-individual variability.  
 
Maternal adipose tissue as a potential source of LC PUFA 
There were no differences in subcutaneous or visceral adipose tissue fatty acid composition 
between Control, PE and IUGR mothers (Tables S4 and S5). The predominant fatty acids in both 
tissues were 16:0, 18:1n-9 and 18:2n-6. Long chain PUFA was a minor component of adipose 
tissue. There were significant differences in subcutaneous adipose tissue ∆5-desaturase (FADS1) 
and ∆6-desaturase (FADS2) mRNA expression between groups (Fig 2A). Subcutaneous adipose 
tissue FADS1 and FADS2 expression in PE was lower than in Controls [mean (SD) Control 3.38 
(2.96) vs PE 1.83 (1.91) square root [sqrt] (FADS1 expression relative to PPIA), P=0.030] and 
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[Control 3.33 (2.25) vs PE 1.03 (0.96) sqrt (FADS2 expression relative to PPIA), P<0.001]. All 
PE subcutaneous adipose tissue samples showed no detectable expression of subcutaneous very 
long chain fatty acid elongase (ELOVL2). There was a significantly higher proportion of 
detectable subcutaneous adipose tissue ELOVL2 expression in Control compared to PE 
(P=0.038). There were no significant differences in FADS1, FADS2 or ELOVL2 mRNA 
expression in visceral adipose tissue (Fig 2B). Stearoyl CoA desaturase (SCD) and long chain 
fatty acid elongase (ELOVL6) mRNA expression did not differ among groups in either 
subcutaneous or visceral adipose tissue. 
 
Placental fatty acid metabolism and transport markers  
To confirm whether low cord levels of 20:3n-6 in the presence of normal levels of 18:2n-6 was 
indicative of low ∆6-desaturase activity in PE and IUGR offspring, ∆6-desaturase (FADS2) 
mRNA expression in a fetal tissue (placenta) was quantitated and found not to be different 
among groups (Figure 2C). In order to test whether lower offspring LC PUFA levels might be 
due to lower placental expression of fatty acid transfer proteins, mRNA expression of placental 
fatty acid transporters (pFABPpm [GOT2] and FABP7) was assessed and found not to differ 
among groups (Figure 2C). The lack of difference in placental gene expression was independent 
of mode of delivery. 
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Discussion 
Absolute amounts of maternal erythrocyte n-6 and n-3 PUFA concentrations were approximately 
60% lower in PE and IUGR compared to Controls and cord blood LC PUFA deficiency is also 
common to PE and IUGR. Low amounts of maternal LC PUFA could result from inhibition of 
synthesis, decreased release from maternal stores and/or reduced acquisition from diet.  
 
In PE the metabolic pattern is of high BMI and high plasma triglyceride and NEFA 
concentrations. Although we could not assess maternal insulin resistance due to the random 
nature of maternal blood samples, second trimester insulin resistance has previously been shown 
to be associated with PE26. The complete biochemical profile of PE women observed here is 
indicative of metabolic syndrome, a biochemical manifestation of insulin resistance which is 
typical of  PE27. The observed reduced adipose tissue ∆5- and ∆6-desaturase and ELOVL2 
expression (Figure S2) suggests that low LC PUFA in PE could be due to decreased synthesis. 
We have previously hypothesized that increased NEFA flux in pregnancy can lead to 
mitochondrial dysfunction2  thus impairing LC PUFA synthesis, analogous to the situation in 
non-alcoholic fatty liver disease which is associated with obesity, insulin resistance and ectopic 
lipid accumulation in the liver. In non-alcoholic fatty liver disease liver LC PUFA are depleted 
possibly via reduced ∆5- and ∆6-desaturase activities3. It was notable that the magnitude of 
reduction in LC PUFA was greater in women with severe PE. 
 
Mothers with IUGR are reported to have low lipolysis rates4 and low BMI28. In IUGR we 
observed trends towards lower maternal erythrocyte concentrations of the major fatty acids 
stored in adipose tissue, 18:1n-9 and 16:029, which is consistent with lower adipocyte lipolysis. 
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The metabolic pattern in IUGR mothers thus may indicate a primary defect in fat storage and 
mobilization from adipose tissue (Figure S2). IUGR cord leptin levels are extremely low 
reflecting reduced adipose tissue depots, however cord triglyceride is high and NEFA 
concentrations normal suggesting that although maternal fatty acid supply may be abnormal, 
there is still fetal capacity for triglyceride synthesis.  
 
The ratio of the n-6 to the n-3 series remains similar among groups suggesting that both 
pathways are affected equally. It is notable that PE and IUGR mothers are not deficient in 20:5n-
3 which suggests it can be synthesized from 18:3n-3. Elongation or desaturation pathways 
downstream of this point may be impaired (Figure S1 and S2). We observed that subcutaneous 
adipose tissue mRNA expression of ∆5- and ∆6-desaturase and very long chain fatty acid 
elongase (ELOVL2 which acts on C20 and C22 fatty acids) was significantly lower in PE 
mothers suggesting compromized synthesis downstream of C20. Adipose tissue is not a major 
site of LC PUFA synthesis but expression here may reflect expression of synthetic enzymes in 
inaccessible tissue e.g. the liver.  
 
It is not known from which maternal stores LC PUFA are mobilized in pregnancy. Potential sites 
are adipose tissue, liver and membranes (including the brain). As in the non-pregnant state29, 
maternal adipose tissue contains reasonable quantities of 18:2n-6, but very little 18:3n-3 and 
minor amounts of LC PUFA. There were also no differences in adipose tissue fatty acid 
composition between groups that could explain the large difference in maternal erythrocyte LC 
PUFA concentrations. Together these data suggest that maternal adipose tissue does not act as a 
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short-term store or site of synthesis of PUFA. It is possible that maternal membrane (brain) and 
liver LC PUFA stores are affected in PE and IUGR especially if synthetic pathways are impeded.  
 
Differing diet between PE and IUGR mothers and Controls is another potential explanation for 
reduced PUFA. The extent of deficiency (up to 60%) would suggest that diets would have to be 
substantially different to have that magnitude of effect on erythrocyte PUFA concentrations. 
Vegan mothers are not specifically susceptible to PE or IUGR30, 31 nor do they demonstrate a 
similar degree of EFA deficiency32. In our study, the ratio of 22:5n-6/22:6n-3, a measure of 
dietary omega-3 or 22:6n-3 deficiency33, was not significantly different between PE cases and 
Controls, further suggesting that diet alone is not the cause of the fatty acid changes. There is 
also no evidence that dietary supplementation with LC PUFA impacts on incidence of PE or 
IUGR34, 35. 
 
The fetus is dependent on the mother for its EFA supply therefore it is not surprising that we 
observed reduced LC PUFA in PE and IUGR offspring. The degree to which the babies are 
deficient is less than expected from the lack of mobilization in the mothers (Fig 1). DHA is an 
extremely important fatty acid for fetal neural development and PE cord blood erythrocytes have 
a lesser degree of DHA deficiency than EFA deficiency (Table 2). This suggests that there are 
mechanisms to compensate such as up-regulation of placental transport or fetal synthesis. There 
was no difference in placental expression of pFABPpm (GOT2) and FABP7 between groups. 
However there are a wide array of placental fatty acid transport proteins16 and a more systematic 
analysis is required to eliminate the possibility of up-regulation of placental fatty acid transport. 
There was a trend towards increased levels of 18:3n-3, the precursor of n-3 PUFA in cord 
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erythrocytes for PE and IUGR. However, placental ∆6-desaturase mRNA expression did not 
differ. Thus there is no evidence for up-regulation of placental or fetal fatty acid synthesis 
pathways. Both PE and IUGR offspring had significantly lower cord blood adiponectin levels 
than controls (Table S2) which may result from reduced n-3 LC PUFA-induced adiponectin 
release from adipocytes36, 37.  
 
The strength of our data is the use of absolute fatty acid concentrations which allows us to 
understand which specific fatty acids are driving the differences in composition between healthy 
and complicated pregnancies. There were limitations to our study. Blood samples were random 
and women were not all fasted which will have an impact on some maternal variables 
(triglyceride and NEFA) but not erythrocyte fatty acid composition. No samples from pre-
pregnancy or early gestation were available for these women. There were few IUGR subjects, the 
PE group were a mixture of primiparous and parous women with potentially different underlying 
risk factors, and there were no dietary intake data.  
 
Perspectives 
At birth, the offspring of PE and IUGR pregnancies are deficient in essential LC PUFA which 
may have long term consequences for their development. The mechanisms by which these 
deficiencies arise differ between PE and IUGR and suggest different interventions. In IUGR LC 
PUFA supplementation may overcome the lack of maternal fatty acid mobilization. In PE 
insulin-sensitizing treatments such as metformin may reduce ectopic fat accumulation and 
upregulate LC PUFA synthetic pathways. 
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Novelty and significance 
1) What is new? 
This study shows that levels of a class of fats that are particularly important for fetal brain 
development (long chain polyunsaturated fatty acids) are lower in maternal and cord blood in 
pregnancies complicated by preeclampsia and intrauterine growth restriction. We provide 
evidence that in preeclampsia this might be due to a decreased ability of the mother to make 
these fats from dietary precursors. 
2) What is relevant? 
The findings are important as they indicate that offspring of pregnancies complicated by 
preeclampsia or intrauterine growth restriction may be at risk of impaired neural development 
and suggest that the approaches to reducing this risk would differ. In preeclampsia, drug 
interventions that may improve the mother’s metabolism and ability to make long chain 
polyunsaturated fatty acids are indicated, whereas in intrauterine growth restriction 
supplementation of the diet with long chain polyunsaturated fatty acids would be indicated. 
3) Summary 
Low maternal and offspring levels of fats important for offspring neural development in 
preeclampsia may be due to an impaired ability of the mother to synthesize them. 
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Figure 1. Maternal (■) and cord (□) plasma polyunsaturated fatty acid (PUFA) concentration 
expressed as a percentage of Control maternal and cord fatty acid concentration respectively in 
pregnancies complicated by A. Preeclampsia (PE). B. Intrauterine growth restriction (IUGR). 
 
Figure 2. A. Maternal subcutaneous adipose tissue gene expression in control (n=50), 
preeclampsia (PE) (n=12) and intrauterine growth restriction (IUGR) (n=13), B. maternal 
visceral adipose tissue gene expression in control (n=25), PE (n=12) and IUGR (n=5), C. 
placental gene expression in control (n=57), PE (n=17) and IUGR (n=11) pregnancy relative to 
control gene (PPIA for adipose tissue and TOP1 for placenta). Means (standard error), of 
transformed (log [GOT2 and FADS2] or square root) target gene expression relative to control 
gene expression values, are presented. * significant difference among groups on ANOVA; # 
significant difference among groups on Kruskal-Wallis test. 
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 Table 1.  Maternal erythrocyte fatty acid concentrations (nmol/mL blood) from third 
trimester Control, preeclampsia (PE) and intrauterine growth restriction (IUGR) mothers 
Values are mean and standard deviation (SD). ANOVA* was used to test for differences among 
groups. Different superscript letters indicate differences between individual groups using post 
hoc Tukey test. Significance level P<0.005. † adjusted for maternal body mass index (BMI), 
parity, smoking status and gestational age at sampling.  
 
Fatty Acid 
 
Control  
(n=164) 
PE 
(n=62) 
IUGR 
(n=23) 
P* †Adjusted 
P 
SAFA      
12:0 0.3 (2) 1.4 (5) 0 (0) 0.026 0.099 
14:0 15 (9) 17 (8) 16 (8) 0.26 0.48 
16:0 516 (116) 531 (107) 447 (128) 0.010 0.016 
17:0 6 (5) 5 (5) 7 (4) 0.21 0.19 
18:0 318 (74) 294 (70) 294 (83) 0.055 0.021 
20:0 11 (4) 10 (4) 11 (4) 0.65 0.11 
22:0 22 (14)a 17 (16)a 9 (12)b <0.001 <0.001 
24:0 60 (12) 61 (17) 61 (13) 0.80 0.85 
MUFA      
14:1n-7 0 (0) 0 (0) 0 (0) - - 
16:1n-7 17 (10) 20 (9) 17 (10) 0.20 0.079 
17:1n-7 17 (28) 15 (27) 15 (27) 0.81 0.69 
18:1n-7 5 (10) 5 (11) 3 (9) 0.71 0.96 
18:1n-9 288 (80) 283 (65) 238 (71) 0.012 0.007 
20:1n-9 8 (5) 6 (5) 6 (4) 0.025 0.007 
22:1n-9 1 (3) 1 (3) 0 (0) 0.21 0.11 
24:1n-9 86 (22)a 80 (20)a,b 70 (21)b 0.002 0.004 
PUFA n-6      
18:2n-6 171 (54)a 130 (51)b 115 (49)b <0.001 <0.001 
18:3n-6 1.8 (3) 1.3 (3) 2.1 (3) 0.43 0.38 
20:2n-6 4 (5)a 2 (3)b 2 (3)b <0.001 <0.001 
20:3n-6 32 (15)a 23 (14)b 20 (11)b <0.001 <0.001 
20:4n-6 225 (89)a 142 (97)b 128 (82)b <0.001 <0.001 
22:2n-6 0.8 (1.8) 0.7 (1.5) 0.8 (1.6) 0.97 0.64 
22:4n-6 43 (20)a 26 (20)b 25 (17)b <0.001 <0.001 
22:5n-6 10 (6)a 5 (6)b 4 (5)b <0.001 <0.001 
PUFA n-3      
18:3n-3 5 (4) 3 (3) 4 (3) 0.028 <0.001 
20:3n-3 1.1 (2.8) 0.1 (0.6) 0 (0) 0.006 0.002 
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20:5n-3 16 (10) 16 (10) 17 (12) 0.91 0.86 
22:3n-3 3.6 (5.1) 2.6 (4.0) 1.5 (2.3) 0.080 0.012 
22:5n-3 32 (14)a 19 (14)b 17 (14)b <0.001 <0.001 
22:6n-3 65 (30)a 40 (35)b 39 (31)b <0.001 <0.001 
Summary indices 
% SAFA 49 (7)a 54 (9)b 56 (10)b <0.001 <0.001 
% MUFA 21 (2)a 23 (2)b 22 (4)a <0.001 <0.001 
% PUFA 30 (7)a 22 (9)b 22 (9)b <0.001 <0.001 
% UNSAT 51 (7)a 46 (9)b 44 (10)b <0.001 <0.001 
UI 131 (29)a 102 (35)b 101 (36)b <0.001 <0.001 
Av CL 18.5 (0.3)a 18.3 (0.3)b 18.3 (0.3)b <0.001 <0.001 
C 20-22 26 (6)a 20 (7)b 21 (6)b <0.001 <0.001 
n-6/n-3 ratio 4.2 (1.2) 4.5 (2.0) 4.5 (2.1) 0.21 0.21 
DHA deficiency 
index 
0.20 (0.11)a 0.13 (0.16)b 0.11 (0.11)b <0.001 <0.001 
EFA deficiency  
index 
1.44 (0.39)a 0.98 (0.42)b 1.02 (0.41)b <0.001 <0.001 
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 Table 2.  Cord erythrocyte fatty acid concentrations (nmol/mL blood) from Control, 
preeclampsia (PE) and intrauterine growth restriction (IUGR) offspring Values are mean 
and standard deviation (SD). ANOVA* was used to test for differences among groups. Different 
superscript letters indicate differences between individual groups using post hoc Tukey test. 
Significance level P<0.005. †adjusted for maternal body mass index (BMI), parity, smoking 
status and gestational age at delivery. 
 
Fatty Acid 
 
Control  
(n=85) 
PE 
(n=21) 
IUGR 
(n=13) 
P* †Adjusted 
P 
SAFA      
12:0 0 (0) 0 (0) 0 (0) - - 
14:0 8 (4)a 11 (5)b 12 (5)b 0.001 0.044 
16:0 429 (99) 446 (78) 451 (90) 0.60 0.81 
17:0 3 (2)a 4 (2)a,b 5 (1)b <0.001 0.045 
18:0 275 (59) 265 (43) 272 (35) 0.74 0.86 
20:0 8 (3) 8 (3) 7 (2) 0.20 0.18 
22:0 21 (7) 19 (4) 17 (5) 0.08 0.044 
24:0 62 (14) 59 (9) 57 (9) 0.31 0.078 
MUFA      
14:1n-7 1.0 (3.8) 1.0 (2.2) 1.5 (3.5) 0.87 0.82 
16:1n-7 10 (6) 10 (5) 8 (2) 0.34 0.53 
17:1n-7 29 (24) 38 (21) 45 (16) 0.023 0.14 
18:1n-7 14 (16) 9 (14) 5 (13) 0.13 0.47 
18:1n-9 171 (54) 168 (38) 163 (33) 0.88 0.82 
20:1n-9 1.5 (1.6) 2.4 (2.6) 2.3 (1.2) 0.087 0.85 
22:1n-9 0.2 (1.1) 0 (0) 0 (0) 0.71 0.38 
24:1n-9 57 (16) 57 (15) 56 (11) 0.97 0.73 
PUFA n-6      
18:2n-6 57 (18) 55(16) 57 (17) 0.91 0.67 
18:3n-6 0.4 (1.1) 0.6 (0.8) 0.9 (1.2) 0.22 0.26 
20:2n-6 5 (6) 4 (6) 5 (4) 0.76 0.094 
20:3n-6 41 (16)a 30 (15)b 27 (11)b 0.002 0.016 
20:4n-6 239 (90) 176 (90) 193 (66) 0.007 0.008 
22:2n-6 1.9 (3.6) 0.4 (1.9) 0 (0) 0.037 0.055 
22:4n-6 48 (19)a 33 (18)b 37 (13)a,b 0.002 0.016 
22:5n-6 18 (8)a 10 (7)b 12 (5)b <0.001 0.006 
PUFA n-3      
18:3n-3 0.08 (0.3) 0.39 (0.8) 0.37 (0.6) 0.011 0.087 
20:5n-3 6.1 (7) 5.0 (8) 2.6 (4) 0.22 0.52 
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22:3n-3 0.1 (0.4) 0 (0) 0 (0) 0.67 0.16 
22:5n-3 11 (5)a 7 (6)b 8 (5)a,b 0.004 0.11 
22:6n-3 73 (33)a 49 (31)b 53 (29)a,b 0.003 0.03 
Summary Indices 
% SAFA 51 (7) 56 (10) 55 (9) 0.007 0.007 
% MUFA 18 (2)a 19 (4)b 19 (2)a,b 0.002 0.094 
% PUFA 31 (7)a 24 (9)b 26 (9)a,b <0.001 0.002 
% UNSAT 49 (7) 44 (10) 45 (9) 0.007 0.007 
UI 141 (29)a 114 (36)b 122 (35)a,b <0.001 0.003 
Av CL 18.7 (0.3)a 18.4 (0.3)b 18.4 (0.3)b <0.001 <0.001 
C 20-22 33 (6.2)a 27 (6.4)b 28 (6.9)b <0.001 <0.001 
n-6/n-3 ratio 4.8 (1.2) 5.1 (2.1) 5.1 (2.0) 0.63 0.98 
DHA deficiency 
index 
0.36 (0.10) 0.30 (0.12) 0.32 (0.08) 0.019 0.13 
EFA deficiency 
index 
1.84 (0.53)a 1.33 (0.55)b 1.48 (0.39)a,b <0.001 0.001 
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Methods 
Subjects 
Blood pressure measurements were taken at all routine antenatal visits by a midwife using an 
automated sphygmomanometer (A&D digital BP machine) in the left arm in a seated position. 
Urinalysis was initially screened using a combiscreen dipstick (Analyticon Biotechnologies) and 
if abnormal on visual screening confirmed on dipstick reader (Combiscan 100, Analyticon 
Biotechnologies). For women recruited just prior to undergoing Caesarean section, pre-operative 
blood pressure was taken using a Dinamap® (GE Healthcare) in the left arm with women in a 
semi-recumbent position and repeat urinalysis was not performed if a recent measurement in 
clinic had been negative. In PE women, third trimester blood pressure measurements were taken 
in the left arm in semi-recumbent position using a Dinamap®. PE was defined according to the 
ISSHP criteria i.e. recruitment of a patient with PE required a reading of diastolic blood pressure 
>110 mmHg on one occasion, or >90 mmHg on repeated readings and being normotensive at 
booking. In addition, urinalysis on dipstick, using the method described above, was greater or 
equal to 2+ proteinuria on at least one occasion in the absence of renal disease or infection, with 
minimal or no proteinuria on previous urinalysis. Women were classified as having severe PE 
according to the Hypertension in Pregnancy NICE clinical guideline 107 i.e. a diastolic blood 
pressure of 110mmHg or greater, and/or a systolic blood pressure 160mmHg or greater. Twenty-
one of the PE mothers were classified as having severe PE and samples were available from 9 
babies from a severe PE pregnancy. IUGR was defined as an estimated fetal weight <5th 
percentile for gestation with associated oligohydramnios (amniotic fluid index <5) and/or 
abnormal umbilical artery blood flow on Doppler ultrasound. Four women with PE also had 
IUGR and were included in the PE group only. Multiparous pregnancies were excluded. None of 
the women had a medical history of metabolic disease or had suspected fetal anomalies likely to 
contribute to reduced fetal growth. Subject characteristics were recorded at time of sampling. 
Delivery details were recorded from patient notes. Deprivation category (DEPCAT score), a 
measure of socioeconomic status, was assigned using the Scottish Area Deprivation Index for 
Scottish postcode sectors, 19981. Customised birth weight centiles were calculated using the 
Gestation Network Centile Calculator 5.4 
(http://www.gestation.net/birthweight_centiles/centile_online.htm). Non-fasting venous blood 
was collected from non-labouring mothers. Plasma was harvested at 5°C by low speed 
centrifugation within 30 minutes of collection and plasma and erythrocytes stored at -80°C. 
Placental biopsies were collected at delivery. Subcutaneous adipose tissue was obtained at 
Caesarean section from under the skin on entry into the abdomen and visceral adipose tissue was 
obtained from the omentum following closure of the uterus and haemostasis. Biopsies were flash 
frozen in liquid nitrogen and stored at -80°C until analyzed. 
 
Plasma metabolites 
Plasma NEFA was quantitated by colorimetric assay (Wako, Alpha Laboratories, Eastleigh, 
UK). Insulin quantitation was performed by ELISA (Mercodia, Sweden)  according to the 
manufacturer’s instructions. HOMA was calculated as follows: [fasting insulin (mU/L) x fasting 
glucose (mmol/L)]/22.5. Plasma leptin, adiponectin, IL-6 and TNFα were assayed by ELISA 
(R&D Systems, Abingdon, UK).  
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Fatty acid compositions 
Erythrocyte membranes were collected as described previously2. An 11µm thick cryosection of 
adipose tissue was extracted by washing with 1mL chloroform:methanol (2:1 vol/vol) and made 
up to a final volume of 5 ml. Fatty acid extracts were prepared by modified Folch extraction and 
derivatised2, 3. Methyl fatty acids were separated, identified and quantitated by gas 
chromatography2, 4. Identification of fatty acid methyl esters was made by comparison with 
authentic standard mixtures (Fatty acid methyl ester mixture #189-19, L9405, Sigma, Sweden). 
Inclusion of heneicosanoic acid or pentadecanoic acid (0.2mg/ml toluene) during extraction 
allowed quantitation of fatty acid absolute concentrations. 
 
Messenger RNA expression 
Total RNA was isolated from placental and adipose tissue using the ABI PRISM 6100 Nucleic 
Acid Prepstation following manufacturer’s instructions (Applied Biosystems, Warrington, UK). 
cDNA was reverse transcribed from RNA using a High Capacity cDNA Reverse Transcriptase 
Kit (Applied Biosystems). Target gene expression was quantitated relative to a control gene 
(TOP1 Hs00243257_m1 placenta5 and PPIA Hs99999904_m1 adipose tissue6) using commercial 
primer probe sets (FADS1 Hs00203685_m1, FADS2 Hs00188654_m1, SCD Hs01682761_m1, 
ELOVL2 Hs00214936_m1, ELOVL6 Hs00225412_m1, GOT2 Hs00905827_g1 and FABP7 
Hs00361426_m1 Applied Biosystems) in a final volume of 25ul on an 7900HT Sequence 
Detection System (Applied Biosystems). The expression of target assays were normalised by 
subtracting the CT value of the endogenous control from the CT value of the target assay. The 
fold increase relative to the control was calculated using the formula 2-∆CT and expressed as a 
percentage. Fold increase data was square root or log transformed to achieve a normal 
distribution before statistical analysis. 
 
Statistical analysis 
Normality testing used the Ryan-Joiner test and, where necessary, data were transformed to log 
or square root values to achieve normality. ELOVL2 expression was undetectable in the entire PE 
group and non-parametric analysis used. Chi squared test was used to test for differences among 
groups for categorical and ANOVA or Kruskal-Wallis for continuous variables. Post hoc 
comparison between groups was by Tukey-Kramer test or by comparison of proportions of 
detectable expression by Fisher’s exact test. Multivariate analysis was carried out using the 
General Linear Model. Statistical analysis was carried out using Minitab (Vs 15.1) or JMP 7. 
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Abbreviations   
12:0 lauric acid; 14:0 myristic acid, 16:0 palmitic acid; 18:0 stearic acid; 20:0 arachidic acid; 
22:0 behenic acid; 24:0 lignoceric acid; 16:1n-7, palmitoleic acid; 18:1n-9 oleic acid; 20:1n-9 
eicosenoic acid, 22:1n-9 erucic acid; 24:1n-9 nervonic acid; 18:2n-6 linoleic acid; 18:3n-6 
gamma-linolenic acid; 20:3n-6 dihomo-gamma-linolenic acid; 20:4n-6 arachidonic acid; 22:4n-6 
adrenic acid; 22:5n-6 docosapentaenoic acid; 18:3n-3 alpha-linolenic acid; 20:3n-3 
eicosatrienoic acid; 20:5n-3 eicosapentaenoic acid; 22:5n-3 docosapentaenoic acid; 22:6n-3 
docosahexaenoic acid (DHA); n-9 omega-9 monounsaturated fatty acids; n-7 omega-7 
monounsaturated fatty acids; n-6 omega-6 polyunsaturated fatty acids; n-3 omega-3 
polyunsaturated fatty acids; BMI body mass index; C20-22 fatty acids with carbon chain length 
of 20 to 22 carbons; CRP C reactive protein; DEPCAT Deprivation score which is a measure of 
socio-economic status; HDL high density lipoprotein; HOMA homeostasis model of assessment; 
ISSHP International Society for the Study of Hypertension in Pregnancy; IUGR intrauterine 
growth restriction; LC long chain; MUFA monounsaturated fatty acids; NEFA non-esterified 
fatty acids; PE preeclampsia; pFABPpm placental plasma membrane fatty acid binding protein; 
PUFA polyunsaturated fatty acid; SAFA saturated fatty acid; SCD stearyl CoA desaturase; 
SHBG steroid hormone binding globulin. 
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Table S1. Maternal antenatal booking characteristics for Control, preeclampsia (PE) and 
intrauterine growth restriction (IUGR) mothers. Values are mean and standard deviation 
(SD) for continuous variables or number (%) for categorical variables. ANOVA* was used to test 
for differences among groups (†on log transformed data). Chi squared test was used to test for 
differences among groups for categorical variables. Different superscript letters indicate 
differences between individual groups using post hoc Tukey-Kramer test or subgroup chi-
squared test. Significance level P<0.005.  
 
Maternal Parameter Control 
(n=164) 
PE 
(n=62) 
IUGR 
(n=23) 
 P* 
Demographic data     
BMI† 
(kg/m2) 
27.8 (5.9) 27.8 (5.5) 24.5 (4.9) 0.021 
Age  
(years) 
29.6 (5.6) 29.1 (6.3) 29.4 (5.4) 0.83 
DEPCAT Score 
 
4.8 (1.8) 4.4 (1.8) 5.3 (1.8) 0.11 
Primigravidae  
(n, %) 
83 (50.3) 43 (69.4) 12 (52.2) 0.039 
Smokers  
(n, %) 
43 (26.1)a 6 (9.8)b 13 (56.5)c <0.001 
Sampling gestation  
(weeks) 
37.4 (2.9) 36.3 (3.2) 36.1 (2.9) 0.028 
Systolic BP†  
(mmHg) 
120 (14)a 152 (19)b 107 (10)a <0.001 
Diastolic BP†  
(mmHg) 
71 (9)a 95 (11)b 71 (7)a <0.001 
Gestation at delivery 
(weeks) 
39.8 (1.4)a 36.7 (3.0)b 36.5 (3.1)b <0.001 
Birth weight  
(g) 
3575 (552)a 2563 (799)b 2018 (565)c <0.001 
Birth weight centile 
 
56.2 (31.6)a 24.1 (27.7)b 2.0 (3.2)c <0.001 
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Table S2. Maternal third trimester plasma and cord plasma metabolic and inflammatory 
markers for Control, preeclampsia (PE) and intrauterine growth restriction (IUGR) 
pregnancies. Values are mean and standard deviation (SD) for continuous variables or number 
(%) for categorical variables. ANOVA* was used to test for differences among (†on log 
transformed or ‡ square root transformed data). Different superscript letters indicate differences 
between individual groups using post hoc Tukey-Kramer test or subgroup chi-squared test. 
Significance level P<0.005. ‡adjusted for maternal body mass index (BMI), parity, smoking 
status and gestational age at sampling (for mothers) or gestational age at delivery (for offspring).  
 
Biochemical Parameter Control 
 
PE 
 
IUGR 
 
 P* §Adjusted 
P 
Maternal plasma (n) n=164 n=62 n=23   
Total cholesterol  (mmol/L) 6.16 (1.08) 6.62 (1.17) 6.27 (1.01) 0.022 0.010 
Triglyceride† (mmol/L) 2.78 (0.99)a 3.36 (1.01)b 2.63 (1.06)a <0.001 <0.001 
HDL cholesterol† (mmol/L) 1.61 (0.38) 1.66 (0.46) 1.70 (0.45) 0.63 0.20 
NEFA† (mmol/L) 0.34 (0.20)a 0.51 (0.23)b 0.52 (0.50)a,b <0.001 <0.001 
Leptin† (mg/mL) 37 (26)a 58 (33)b 34 (27)a 0.001 0.002 
Adiponectin† (ug/mL) 8.3 (3.2)a 10.7 (4.7)b 8.5 (3.3)a,b 0.002 <0.001 
IL-6† (pg/mL) 2.6 (1.6)a 4.7 (4.8)b 2.7 (1.8)a 0.001 <0.001 
TNFα† (pg/mL) 1.96 (2.02) 1.71 (0.93) 3.44 (5.28) 0.11 0.62 
CRP† (mg/L) 5.50 (4.81) 7.44 (11.28) 5.36 (3.89) 0.99 0.98 
      
Cord blood (n)  n=85 n=21  n=13 P* §Adjusted 
P 
Total cholesterol† (mmol/L) 1.62 (0.47)a 2.27 (0.68)b 1.22 (0.32)c <0.001 <0.001 
Triglyceride† (mmol/L) 0.45 (0.39)a 0.58 (0.07)b 0.59 (0.22)b 0.004 0.003 
HDL cholesterol† (mmol/L) 0.78 (0.25)a 0.81 (0.30)a 0.44 (0.17)b <0.001 <0.001 
NEFA† (mmol/L) 0.13 (0.10) 0.14 (0.09) 0.15 (0.14) 0.36 0.37 
Glucose† (mmol/L) 4.31 (1.23) 4.57 (0.97) 4.48 (1.28) 0.47 0.68 
Insulin‡ (mU/L) 8.2 (12.3) 10.2 (15.7) 5.5 (9.3) 0.058 0.14 
HOMA† 1.7 (3.7) 2.2 (3.5) 1.1 (1.7) 0.17 0.10 
Leptin† (mg/mL) 13.1 (14.3)a 7.1 (6.8)b 4.2 (6.2)b <0.001 0.57 
Adiponectin (ug/mL) 0.93 (0.41)a 0.58 (0.59)b 0.37 (0.44)b <0.001 0.23 
IL-6† (pg/mL) 6.74 (8.44) 6.79 (5.86) 6.68 (5.68) 0.42 0.66 
TNFα† (pg/mL) 2.31 (1.26) 1.90 (0.60) 2.57 (0.76) 0.063 0.15 
CRP ‡ (mg/L) 0.27 (1.06) 0.11 (0.08) 0.05 (0.06) 0.14 0.26 
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Table S3. Maternal antenatal booking characteristics and third trimester plasma metabolic 
and inflammatory markers and maternal erythrocyte fatty acid concentrations (nmol/mL 
blood) for Control, mild preeclampsia (PE) and severe PE mothers. Values are mean and 
standard deviation (SD) for continuous variables or number (%) for categorical variables. 
ANOVA* was used to test for differences among groups (†on log transformed data). Chi squared 
test was used to test for differences among groups for categorical variables. Different superscript 
letters indicate differences between individual groups using post hoc Tukey-Kramer test or 
subgroup chi-squared test. Significance level P<0.005.  
 
Maternal Parameter Control 
(n=164) 
Mild PE 
(n=38) 
Severe PE 
(n=21) 
 P* 
Demographic data     
BMI (kg/m2) 27.8 (5.9) 28.0 (5.4) 27.4 (5.8) 0.89 
Smokers (n, %) 43 (26.1)a 2 (5.3)b 4 (23.8)a,b 0.004 
Systolic BP† (mmHg) 120 (14)a 142 (13)b 171 (12)c <0.001 
Diastolic BP† (mmHg) 71 (9)a 91 (10)b 103 (9)c <0.001 
Gestation at delivery(weeks) 39.8 (1.4)a 37.2 (2.9)b 36.1 (3.2)b <0.001 
Birth weight (g) 3575 (552)a 2702 (816)b 2377 (703)b <0.001 
Birth weight centile 56.2 (31.6)a 29.1 (32.1)b 16.3 (15.2)b <0.001 
Biochemical data     
Triglyceride†  (mmol/L) 2.78 (0.99)a 3.38 (1.00)b 3.19 (0.88)a,b <0.001 
NEFA† (mmol/L) 0.34 (0.20)a 0.53 (0.26)b 0.54 (0.19)b <0.001 
Leptin†  (mg/mL) 37 (26)a 61 (33)b 51 (32)a,b <0.001 
Adiponectin†  (ug/mL) 8.3 (3.2)a 10.6 (4.9)b 10.9 (4.6)b 0.003 
IL-6† (pg/mL) 2.6 (1.6)a 3.9 (2.6)b 5.5 (6.3)b 0.002 
Fatty Acid     
SAFA     
22:0 22 (14)a 24 (14)a 9 (15)b <0.001 
PUFA n-6     
18:2n-6 171 (54)a 141 (52)b 110 (47)b <0.001 
20:2n-6 4 (5)a 2 (3)b 2 (3)b <0.001 
20:3n-6 32 (15)a 25 (14)b 18 (14)b <0.001 
20:4n-6 225 (89)a 161 (99)b 102 (81)c <0.001 
22:4n-6 43 (20)a 31 (20)b 18 (17)c <0.001 
22:5n-6 10 (6)a 6 (6)b 3 (4)b <0.001 
PUFA n-3     
22:5n-3 32 (14)a 22 (15)b 12 (10)c <0.001 
22:6n-3 65 (30)a 48 (38)b 25 (25)c <0.001 
Summary indices     
% SAFA 49 (7)a 53 (9)b 58 (7)c <0.001 
% MUFA 21 (2)a 23 (2)b 23 (2)b <0.001 
% PUFA 30 (7)a 24 (9)b 18 (8)c <0.001 
% UNSAT 51 (7)a 47 (9)b 42 (7)c <0.001 
UI 131 (29)a 109 (35)b 87 (29)c <0.001 
Av CL 18.5 (0.3)a 18.3 (0.3)b 18.1 (0.3)c <0.001 
C 20-22 26 (6)a 22 (7)b 17 (6)c <0.001 
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DHA deficiency index 0.20 (0.11)a 0.15 (0.15)b 0.09 (0.17)b <0.001 
EFA deficiency  index 1.44 (0.39)a 1.06 (0.42)b 0.81 (0.39)b <0.001 
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Table S4. Fatty acid composition (mol% of total fatty acids) and summary indices in 
subcutaneous adipose tissue from Control, preeclampsia (PE) and intrauterine growth 
restriction (IUGR) mothers biopsied at delivery.  
All values are mean and standard deviation (SD). ANOVA* was used to test for differences 
among groups (†on log transformed where appropriate). Lipogenic index is represented by 
18:2n-6/16:0.  
 
Fatty acid 
 
Control 
n=28 
PE 
n=13 
IUGR 
n=5 
*P 
Mol% of Total Fatty Acids 
SAFA     
12:0 0.58 (0.44) 0.45 (0.21) 0.66 (0.22) 0.45 
14:0 2.98 (0.64) 2.89 (0.50) 3.00 (0.76) 0.88 
16:0 24.0 (1.7) 23.7 (1.8) 23.3 (2.2) 0.67 
18:0 3.63 (0.84) 3.18 (0.76) 3.71 (0.48) 0.21 
20:0 0.12 (0.05) 0.13 (0.05) 0.16 (0.04) 0.27 
MUFA     
14:1n-7 0.12 (0.14) 0.09 (0.09) 0.16 (0.14) 0.52 
16:1n-7 5.21 (1.19) 5.56 (1.15) 5.60 (0.95) 0.61 
18:1n-7 1.92 (0.50) 1.84 (0.27) 1.39 (0.71) 0.073 
18:1n-9 47.2 (2.5) 47.9 (2.9) 48.1 (2.7) 0.65 
20:1n-9 0.61(0.35) 0.60 (0.35) 0.78 (0.19) 0.56 
PUFA n-6     
18:2n-6 12.1 (2.2) 12.2 (2.2) 11.8 (1.8) 0.93 
18:3n-6 0.08 (0.04) 0.11 (0.03) 0.10 (0.03) 0.069 
20:3n-6 0.18 (0.07) 0.20 (0.12) 0.10 (0.04) 0.093 
20:4n-6 0.26 (0.06) 0.27 (0.10) 0.25 (0.05) 0.89 
PUFA n-3     
18:3n-3 0.89 (0.28) 0.90 (0.22) 0.86 (0.11) 0.95 
20:5n-3 0.01 (0.01) 0.01 (0.02) 0.02 (0.02) 0.45 
22:5n-3 0.005 (0.017) 0.017 (0.040) 0.00 (0.00) 0.30 
22:6n-3 0.01 (0.03) 0.02 (0.04) 0.03 (0.06) 0.54 
Summary Indices 
% SAFA 31.3 (3.0) 30.3 (2.4) 30.9 (3.2) 0.56 
% MUFA 55.1 (3.1) 56.0 (3.7) 56.0 (2.2) 0.65 
% PUFA† 13.6 (2.3) 13.7 (2.4) 13.1 (1.9) 0.89 
% UNSAT 68.7 (3.0) 69.7 (2.4) 69.1 (3.2) 0.56 
% n-6 PUFA† 12.7 (2.2) 12.8 (2.3) 12.2 (1.9) 0.90 
% n-3 PUFA  0.91 (0.28) 0.95 (0.23) 0.90 (0.10) 0.88 
n-6/n-3 ratio 16.4 (12.9) 13.9 (2.9) 13.6 (1.8) 0.71 
Lipogenic Index  0.51 (0.11) 0.52 (0.10) 0.51 (0.12) 0.98 
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Table S5. Fatty acid composition (mol% of total fatty acids) and summary indices in 
visceral adipose tissue from Control, preeclampsia (PE) and intrauterine growth restriction 
(IUGR) mothers biopsied at delivery. 
All values are mean and standard deviation (SD). ANOVA* was used to test for differences 
among groups (†on log transformed where appropriate). Different superscript letters indicate 
differences between individual groups using post hoc Tukey-Kramer test. Lipogenic index is 
represented by 18:2n-6/16:0.  
 
Fatty acid Control 
n=26 
PE 
n=13 
IUGR 
n=5 
*P 
Mol% of total fatty acids 
SAFA     
12:0 0.56 (0.13)a 0.52 (0.13)a 0.87 (0.38)b 0.001 
14:0 3.22 (0.61) 2.99 (0.61) 3.49 (1.00) 0.34 
16:0 23.1 (1.7) 22.7 (1.9) 24.2 (3.3) 0.37 
18:0 4.46 (0.83)a,b 3.90 (0.95)a 5.07 (0.86)b 0.036 
20:0 0.27 (0.06) 0.23 (0.07) 0.29 (0.06) 0.099 
MUFA     
14:1n-7 0.22 (0.18) 0.25 (0.20) 0.11 (0.11) 0.34 
16:1n-7 5.32 (1.01) 5.58 (1.24) 4.94 (0.71) 0.51 
18:1n-7 0.75 (0.82) 0.99 (0.87) 0.71 (0.78) 0.50 
18:1n-9 47.6 (3.4) 48.2 (34.0) 46.5 (3.8) 0.69 
20:1n-9 0.81 (0.36) 0.83 (0.30) 0.84 (0.08) 0.98 
PUFA n-6     
18:2n-6 12.3 (2.2) 12.3 (2.6) 11.9 (1.6) 0.91 
18:3n-6 0.06 (0.03) 0.08 (0.03) 0.07 (0.02) 0.44 
20:3n-6 0.12 (0.05) 0.16 (0.05) 0.11 (0.06) 0.047 
20:4n-6 0.231 (0.07) 0.24 (0.12) 0.19 (0.06) 0.60 
PUFA n-3     
18:3n-3 0.84 (0.25) 0.81 (0.23) 0.70 (0.20) 0.48 
20:5n-3 0.04 (0.04) 0.04 (0.06) 0.04 (0.04) 0.57 
22:5n-3 0.05 (0.05) 0.06 (0.07) 0.03 (0.06) 0.49 
22:6n-3 0.02 (0.04) 0.02 (0.04) 0.03 (0.07) 0.82 
Summary Indices 
% SAFA 31.6 (2.8) 30.4 (2.9) 33.9 (5.4) 0.11 
% MUFA 55.1 (3.1) 55.9 (4.1) 53.1 (4.2) 0.37 
% PUFA† 13.6 (2.2) 13.8 (2.7) 13.0 (1.7) 0.85 
% UNSAT 68.4 (2.8) 69.6 (2.9) 66.1 (5.4) 0.11 
% n-6 PUFA† 12.7 (2.1) 12.8 (2.6) 12.2 (1.7) 0.88 
% n-3 PUFA  0.95 (0.27) 0.95 (0.19) 0.80 (0.25) 0.44 
n-6/n-3 ratio 14.5 (5.0) 13.9 (3.5) 16.8 (6.0) 0.49 
Lipogenic Index  0.54 (0.10) 0.55 (0.13) 0.50 (0.14) 0.78 
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Figure S1. Mammalian fatty acid synthesis pathways. Mammalians can synthesize saturated 
and monounsaturated fatty acids. The substrates for long chain polyunsaturated fatty acid (LC 
PUFA) synthesis, 18:2n-6 and 18:3n-3 cannot be made by mammals and required to be derived 
from the diet. The n-6 LC PUFA and n-3 LC PUFA biosynthetic pathways are carried out in 
parallel and share the same elongase and desaturase enzymes.
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Figure S2.  Long chain polyunsaturated fatty acid metabolism (LC PUFA) metabolism in 
preeclampsia (PE) and intrauterine growth restriction (IUGR) pregnancy. Sources that 
contribute to the maternal circulating LC PUFA pool include de novo synthesis from shorter 
chain essential fatty acid precursors in the liver and other tissues, dietary intake and release from 
maternal stores via lipolysis. Others have shown that lipolysis is increased in PE and reduced in 
IUGR. We provide evidence that LC PUFA synthesis is decreased in PE via reduced FADS1, 
FADS2 and ELOVL2 expression. LC PUFA are transported across the placenta and together with 
LC PUFA that might be synthesised de novo in the placenta contribute to the fetal LC PUFA 
pool. We observed no difference in the mRNA expression of placental transport proteins specific 
for 22:6n3 between control and PE or IUGR pregnancies. The fetus requires LC PUFA for the 
synthesis of membranes and brain development. 
 
 
